Cheers,
We’ve recently released an Initiation of Coverage Report on Faron Pharmaceuticals. Faron is a clinical stage drug development company focused on immunology. The lead candidate bexmarilimab is an immuno oncology drug developed for various solid tumors and blood cancers. The full report is availabe to all readers freely. Feel free to ask any questions you may have on the investment case and please remember to tag my name to avoid missing your question.
-Antti, Analyst, Life Sciences
Det här är en över ett halvår gammal video om företaget, men den är ändå bra att titta på om man är intresserad av företaget. Antti är verkligen en utmärkt analytiker.
Faron Pharmaceuticals is a drug development company. Faron is a very high-risk investment as drug development requires frontloaded investments in research, while the success of commercialization is very uncertain. Analyst Antti Siltanen elaborates.
00:00 Antti, what do Faron do in very simple terms? 02:50 The drug candidates 05:30 The biggest risks and uncertainties? 08:50 It’s very probable Faron goes bankrupt and investors loose their money, but on the other hand if a miracle happens the pay off is huge. Why do have an accumulate recommendation to the stock?
Hi Börsen,
Although a bit old, the video and our Initiation of Coverage report are mostly still relevant. The main developments since recording the vid have been the faster than expected development of the phase I/II BEXMAB trial investigating bexmarilimab for treatment of blood cancers. On the other hand, development of the other two bexmarilimab trials MATINS (bex monotherapy in solid tumors) and BEXCOMBO (bex combined with PD-1 inhibitors) have been a bit slower than we anticipated probably due to lack of funding. We commneted on biotech funding recently here.
We will be updating our extensive report by the end of the year and provide regular updates on the stock in the mean time. The latest one is Faron Pharmaceuticals: BEXMAB study’s good momentum supports valuation
Hello Antti!
Thank you very much for your response and also for the excellent analyses!
Without you, interpreting a company like this would be very difficult for me alone. The industry is so challenging for an ordinary investor like myself.
You’re doing a great job, and I appreciate it! 
A little news from Faron:
On Wednesday, Faron Pharmaceuticals published new positive results from the BEXMAB study to examine the efficacy of the company’s precision immunotherapy treatment (bexmarilimab) for a number of malignant haematological tumors, or blood cancers. Faron also stated that they plan to file the first Biologics License Application (BLA) to FDA in H1’25.
Aktiekursens samtidiga uppgång har emellertid försämrat förhållandet mellan avkastning och risk. Under det kommande året är en central drivkraft för aktieavkastningen resultaten från fas II av blodcancerstudien BEXMAB och finansiella lösningar, där Faron har hänvisat till pågående diskussioner om licensavtal.
Faron-aktiens värde har stigit betydligt och är oväntat väl följt i Finland.
Under det kommande året verkar resultaten från fas II av BEXMAB-studien vara av särskilt intresse, liksom finansiella arrangemang där Faron har antytt att de förhandlar om ett licensavtal. Åtminstone så har jag förstått från Inderes-analytikernas resonemang.
Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting
https://otp.tools.investis.com/clients/uk/faron2/rns/regulatory-story.aspx?cid=2223&newsid=1741052
Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine
https://otp.tools.investis.com/clients/uk/faron2/rns/regulatory-story.aspx?cid=2223&newsid=1740511
Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS
https://otp.tools.investis.com/clients/uk/faron2/rns/regulatory-story.aspx?cid=2223&newsid=1731417
The Board of Directors of Faron Has Resolved on a Warrant Program and an Issuance of 319,944 Warrants to IPF Partners
https://otp.tools.investis.com/clients/uk/faron2/rns/regulatory-story.aspx?cid=2223&newsid=1731388
Faron to present Phase 1/2 data from BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting
https://otp.tools.investis.com/clients/uk/faron2/rns/regulatory-story.aspx?cid=2223&newsid=1730959
Faron Pharmaceuticals is developing several promising drug candidates, with the most advanced being Bexmab intended for the treatment of mantle cell lymphoma. Bexmab shows significant potential in cancer treatment, but drug development carries inherent risks, and success is not guaranteed.
The company currently operates at a loss, with profitability uncertain in the future. Despite a decline in Faron’s stock price, the investment offers potential for high returns but also the risk of the stock becoming worthless.
Through an offering, the company raised 27 million euros, sufficient to fund the completion of Bexmab’s Phase II clinical development and preparation for Phase III until approximately Q1/2025. Faron plans to negotiate a licensing or collaboration agreement to support Bexmab’s further development.
There is considerable discussion about the company online, so it is advisable to approach opinions from internet commentators with caution. 
New series of articles!
We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they can apply for marketing authorization and commercialize a drug.
Part 2 of the article series!
Probabilities of success in drug development
The second part of our series of articles focusing on the basics of investing in Life Science companies deals with the likelihood of successful drug development. Drug development companies typically examine the safety, tolerability and efficacy of a drug candidate in three clinical phases…
Faron received an Innovation Passport in the UK for the treatment of relapsed/refractory myelodysplastic syndrome (r/r MDS) and will initiate the BEXMAB trial, accelerating drug development and patient access to treatments.
Faron presented more detailed interim results from the BEXMAB study at the ASH conference. The data supports earlier positive findings: 80% of patients achieved a treatment response, with response types predicting longer life expectancy. The life expectancy estimate remained at 13.4 months, but stronger results are expected by the end of Q3 2025. The crucial final report will be released at the end of March 2025, which is also a potential timing for partnership announcements.
Below is a recent analyst report on the company. 